Lifecore Biomedical Inc. (LFCR)
NASDAQ: LFCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LFCR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $242.22M
- EPS (TTM)
- -$1.27
- Dividend yield
- None
- 52-week range
- 3.63 – 8.98
- Day range
- 6.37 – 6.39
- Volume / Avg
- 218.74K / 414.71K
- Beta
- —
- Shares outstanding
- 37.91M
52-week range
LFCR stock today
Shares of Lifecore Biomedical (LFCR) finished higher on Nov 20 at $6.39, a gain of 0.31% or $0.02 per share, versus the S&P 500's 3.70% decline. Shares are 28.8% below their 52-week high of $8.98, set on Jan 27, 2026 and 76.0% above the 52-week low of $3.63, in the middle of the past year's range. LFCR is down 21.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 16.4%.
Lifecore Biomedical has posted a net loss over the last twelve months (EPS of -$1.27), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lifecore Biomedical
Company profileLifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Paul Josephs
- Headquarters
- Chaska, MN
- Employees
- 382
- Website
- lifecore.com
Financial highlights
Full financialsIn fiscal 2025, Lifecore Biomedical generated $128.9 million in revenue, up 0.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Lifecore Biomedical reported a net loss of $38.7 million, compared with net income of $12.0 million a year earlier. Gross margin was 31.3% (down from 32.6%) and operating margin -13.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $128.87M | $128.26M | $103.27M | $111.27M | $100.87M |
| Growth | +0.47% | +24.20% | -7.19% | +10.31% | -36.98% |
| Net income | $-38.72M | $12.01M | $-99.56M | $-116.72M | $-32.29M |
| EPS (diluted) | $-1.27 | $0.33 | $-3.32 | $-3.97 | $-1.10 |
Analyst forecast
ForecastConsensus (5 analysts)
hold
Avg. price target
$6.28-1.72%
- Strong buy 0
- Buy 0
- Hold 5
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-1.08 vs $-0.30
- Surprise
- -260.00%
LFCR news
All LFCR newsLifecore Biomedical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CAMPCAMP4 Therapeutics Corporation | 3.79 | -5.25% | $237.84M | vs LFCR |
| TTRXTurn Therapeutics Inc. | 8.10 | -6.31% | $247.49M | vs LFCR |
| QTTBQ32 Bio Inc. | 8.34 | -1.65% | $249.57M | vs LFCR |
| PRLDPrelude Therapeutics Incorporated | 3.23 | -0.77% | $258.63M | vs LFCR |
| ALTAltimmune Inc. | 1.33 | -5.67% | $258.80M | vs LFCR |
| EBSEmergent BioSolutions Inc. | 5.05 | -1.94% | $259.65M | vs LFCR |
| ENTAEnanta Pharmaceuticals Inc. | 7.62 | -4.51% | $222.19M | vs LFCR |
| IMRXImmuneering Corporation Class A | 3.38 | -2.03% | $218.90M | vs LFCR |
Indexes, lists and sector
Lifecore Biomedical stock FAQ
What is Lifecore Biomedical's stock price today?
LFCR last traded at $6.39 as of Nov 20, 4:00 PM EST, up 0.31% on the day. Prices are delayed at least 15 minutes.
Who is Lifecore Biomedical's CEO?
Mr. Paul Josephs is the chief executive officer of Lifecore Biomedical Inc., which has about 382 employees.
What is the LFCR 52-week high?
The 52-week high for LFCR is $8.98 and the 52-week low is $3.63. The stock is currently 28.8% below its high.